Merck KGaA, Darmstadt, Germany, which operates its Healthcare business as EMD Serono in the U.S. and Canada, shared updates on its healthcare strategy, aimed at doubling R&D productivity. The goal is to introduce one new product or major indication every 1.5 years on average by focusing its expertise and capabilities and leverage synergies within the existing pipeline to deliver transformative medicines in Oncology, Neurology and Immunology, augmented by an increased focus on external innova...